Investing at the intersection of AI x Bio or new mechanisms in cardiovascular disease?
Reach out to our CEO for more information on how to join the movement!
Fauna at a Glance:
Pipeline & Platform Highlights
Lead program — FAUN1083
Program identified directly from Fauna’s ConvergenceAI platform
Lead development candidate nominated
IND-enabling studies initiated in Q4 2025
Novel MOA that complements current SOC therapy
On track for first-in-human clinical entry in 2026
Presented this year at AHA
Large market opportunity
FAUN1083 is a potential best-in-class therapy for patients with HFpEF
Addressable U.S. population: approximately 3 million patients (~20million patients globally)
Estimated $4B peak sales potential (US)
Pipeline strategy focused on large markets with significant unmet need
>80B market potential for broader set of indications available through platform and data approach
Novel discovery platform
AI-enabled genomics engine supported by proprietary datasets in natural disease resistance
Modality-agnostic platform capable of supporting multiple therapeutic approaches
Expanding into broader cardiometabolic and chronic disease applications
Pharma validation
Platform and approach validated through multiple collaborations with leading pharmaceutical companies
Independent confirmation of scientific robustness and strategic value
Exploring additional partnerships in cardiorenal, CNS and immune/inflammatory
Experienced team and advisors
102 cumulative years of drug-development experience
Track record includes 13 approved drugs, more than 30 clinical candidates, and over 125 filed patents
Deep expertise in cardiometabolism, translational research, and clinical development
Fauna advisors have generated 13.4B in deal value through acquisitions and partnering
Capital efficiency & Series A use of proceeds
All progress to date achieved with only $23M in invested capital
Demonstrated ability to execute discovery, platform development, and pipeline advancement with high efficiency
Funding will enable FAUN1083 clinical proof-of-concept studies in Group 2 PH / HFpEF
Fauna Bio has been featured on:
And Recognized By:
**Note, Fauna Bio is not a public company and can only take investments from accredited investors**
